Loading clinical trials...
Loading clinical trials...
Open, Multicenter Phase IV Study, Evaluating Drop of Hemoglobin in Association to the Rate of Sustained Virological Response in Chronic Hepatitis C Patients Treated With Ribavirin (Copegus®) in Combination With Standard Treatment (ANECO)
Conditions
Interventions
peginterferon alfa-2a [Pegasys]
ribavirin [Copegus]
Locations
1
Czechia
Most, Czechia
Start Date
January 1, 2012
Primary Completion Date
January 1, 2014
Completion Date
January 1, 2014
Last Updated
July 24, 2015
NCT05870969
NCT03987503
NCT04382404
NCT01226797
NCT00062816
NCT04774107
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions